Key data from Boehringer Ingelheim's hepatitis C virus clinical trial programme

Key data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical trial programme, HCVerso^TM, focusing on interferon-free treatment, has been selected for inclusion in the official European Association for the Study of the Liver (EASL) press office activities. These data are one of five abstracts from a range of new Boehringer Ingelheim HCV data that have been accepted for presentation at the International Liver Congress (ILC)^TM 2012, taking place 18^th - 22^nd April in Barcelona, Spain.

Boehringer Ingelheim's accepted abstracts not included in EASL media activities can be accessed through the EASL website today, www.easl.eu. The Boehringer Ingelheim data included in EASL media activities will remain under embargo until the time of presentation on 21^st April. All Boehringer Ingelheim's data presentations are listed below.

Collectively, these data underscore the company's focus on finding answers to the challenges faced by HCV patients.

Boehringer Ingelheim is continuing to support its aim of delivering a simpler HCV cure for all patients, including those toughest to treat through the company's rigorous clinical trial programme; HCVerso^TM.